Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
Pipe S, Hermans C, Chitlur M, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak‐Göttl U, Recht M, Chrisentery‐Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Young G, Alexander W, Bonzo D, Macie C, Mitchell I, Sauty E, Wilkinson T, Shapiro A. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia 2022, 28: 548-556. PMID: 35475308, PMCID: PMC9542908, DOI: 10.1111/hae.14563.Peer-Reviewed Original ResearchConceptsInitial dosing regimensControl of bleedingYears of ageEptacog betaBleeding episodesHemophilia ATreatment-related adverse eventsPhase 3 clinical trialsAlternative haemostatic agentModerate bleeding episodesTreat bleeding episodesTreatment of bleedingTreatment success criteriaSuccess proportionRandomised crossover designDosing regimensBeta infusionPaediatric subjectsAdverse eventsBlood productsHaemostatic agentsBleedingEffective treatmentAllergic reactionsNeutralising antibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply